Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma

Clin Nucl Med. 2022 Feb 1;47(2):e152-e153. doi: 10.1097/RLU.0000000000003870.

Abstract

18F-FDG PET/CT imaging series were acquired on a 64-year-old woman with refractory diffuse large B lymphoma to monitor chimeric antigen receptor (CAR) T-cell therapy. Because of a clinical deterioration, 18F-FDG PET/CT performed 8 days after CAR T-cell therapy suggested an early flare-up phenomenon with new lymph node involvement, lymph node progression while a decrease in metabolic tumor volume. The 18F-FDG PET/CT 1 month after CAR T-cell therapy confirmed this hypothesis. Pseudoprogression in solid tumors treated by immunotherapy has generally been reported later after treatment.

Publication types

  • Case Reports

MeSH terms

  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Immunotherapy, Adoptive
  • Lymphoma*
  • Middle Aged
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography

Substances

  • Fluorodeoxyglucose F18